Evidence Map v1

See the shape of every peptide record

Compare selected trials, PubMed bibliography, regulatory records, source-year reach, structured detail, and known collection gaps across all 41 canonical profiles.

Choose your view

Compare two or three peptides

Inspect selected evidence side by side. These collections cover different studies, populations, and dates; they cannot establish which treatment is better. Registry phases describe study records, not results.

Showing Semaglutide and Tirzepatide. Column order is not a ranking.

On a narrow screen, scroll the table horizontally to see every selected profile.

Selected evidence, coverage gaps, and source dates
Evidence dimension	Abaloparatide	Afamelanotide	Amycretin	BPC-157	Bremelanotide	Cagrilintide	CJC-1295	Dulaglutide	Elamipretide	Emideltide	Epitalon	Exenatide	GHK-Cu	Glucagon	Insulin glargine-aldy	Ipamorelin	KPV	Lanreotide	Leuprolide	Linaclotide	Liraglutide	Lixisenatide	Maridebart cafraglutide	Mazdutide	MOTS-c	Octreotide	Pemvidutide	Petrelintide	Plecanatide	Pramlintide	Retatrutide	Semaglutide	Semax	Setmelanotide	Survodutide	TB-500	Teriparatide	Tesamorelin	Tirzepatide	Vosoritide	Ziconotide
Reviewed human evidence	Three selected primary reports in osteoporosis: ACTIVE, its ACTIVExtend follow-up, and ATOM. The extension follows participants from ACTIVE rather than providing an independent replication.^↗^↗^↗ Read the reviewed studies and limitations →	Four selected reports cover randomized trials in erythropoietic protoporphyria (EPP), an observational EPP cohort, combination treatment in vitiligo, and an exploratory stroke study. This is a selected overview, not a completed systematic review.^↗^↗^↗^↗ Read the reviewed studies and limitations →	Five selected reports cover early oral and subcutaneous amycretin studies, later phase 2 diabetes reports using the name zenagamtide, and a renal-function pharmacokinetic study. The two phase 2 reports describe separate route cohorts within one registered protocol.^↗^↗^↗^↗^↗ Read the reviewed studies and limitations →	A bounded review of one human safety pilot, one literature-and-patent review, and one current human trial protocol.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports cover a phase 2 dose-finding trial, the two phase 3 RECONNECT trials, and a safety analysis that reuses development-program participants. Other populations and formulations are outside this synthesis.^↗^↗^↗ Read the reviewed studies and limitations →	Six selected reports include cagrilintide alone and the cagrilintide-semaglutide combination known as CagriSema. The later combination trials address different populations and questions from the earlier cagrilintide-alone study.^↗^↗^↗^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports examine a long-acting CJC-1295 preparation in healthy adults, including a serum-protein analysis. Hormone and protein measurements are distinct from patient benefit; publication count is not a count of independent cohorts.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports cover the randomized Barth syndrome study, follow-up of the same cohort, and a separate primary mitochondrial myopathy trial. They do not cover every indication or replace the product-specific regulatory record.^↗^↗^↗ Read the reviewed studies and limitations →	Two selected small studies examined delta sleep-inducing peptide (DSIP) in chronic insomnia. Their short observation periods and incompletely described formulations limit transfer to other preparations or uses.^↗^↗ Read the reviewed studies and limitations →	Two selected reports discuss the tetrapeptide epitalon/AEDG: a mixed animal-and-human retinal report and a human circadian-biomarker report. This is not a review of the distinct pineal extract epithalamin.^↗^↗ Read the reviewed studies and limitations →	A bounded review of two randomized placebo-controlled trials in type 2 diabetes: one short monotherapy trial and one large cardiovascular-outcomes trial.^↗^↗ Read the reviewed studies and limitations →	Three selected human reports cover topical wound and post-laser skin care, plus a multi-ingredient intradermal hair formulation containing copper tripeptide-1. Formulation and route are kept separate. This is not an exhaustive review of GHK or GHK-Cu.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports examine glucagon rescue formulations in diabetes. Nasal, intramuscular and ready-to-use subcutaneous products have different delivery contexts; related analogues and diagnostic uses require separate assessment.^↗^↗^↗ Read the reviewed studies and limitations →	No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage →	Four selected reports cover intravenous ipamorelin in bowel-surgery patients and healthy volunteers, plus analytical reports involving nasal exposure. These different purposes and routes do not establish benefit for other proposed uses.^↗^↗^↗^↗ Read the reviewed studies and limitations →	No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage →	Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.^↗^↗^↗ Read the reviewed studies and limitations →	A bounded review of two randomized comparisons involving leuprolide: one pelvic-pain trial and one androgen-deprivation trial using leuprolide as the active comparator.^↗^↗ Read the reviewed studies and limitations →	Two publications report adult chronic-constipation trials and a pediatric functional-constipation trial. They do not cover the full irritable-bowel-syndrome program or every currently labeled age group.^↗^↗ Read the reviewed studies and limitations →	A bounded review of two sponsor-funded randomized trials: one 56-week weight-management trial and one cardiovascular-outcomes trial in type 2 diabetes.^↗^↗ Read the reviewed studies and limitations →	Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.^↗^↗ Read the reviewed studies and limitations →	Two selected reports describe early development and a phase 2 trial of an antibody–peptide conjugate combining GIP-receptor antagonism with GLP-1-receptor agonism. Animal experiments and human trial results are separate evidence.^↗^↗ Read the reviewed studies and limitations →	Four selected trials examine mazdutide in adults with obesity or type 2 diabetes in China and the United States. Trial populations, comparators and statistical estimands differ and should not be used to rank results across studies.^↗^↗^↗^↗ Read the reviewed studies and limitations →	Three selected human reports measured naturally occurring MOTS-c during exercise studies or in patients with coronary endothelial dysfunction. None of these reports tested administering MOTS-c to people.^↗^↗^↗ Read the reviewed studies and limitations →	A bounded review of two randomized acromegaly trials: a short placebo-controlled study and a Phase 3 maintenance comparison in patients already responsive to somatostatin receptor ligands.^↗^↗ Read the reviewed studies and limitations →	Two selected reports examine liver-fat changes during an extension study and histologic outcomes in a phase 2 trial. The extension continues an earlier participant cohort; it is not a separate randomized trial.^↗^↗ Read the reviewed studies and limitations →	One selected publication reports two randomized phase 1 trials of petrelintide. This overview concerns early pharmacology, tolerability and weight observations, without a direct comparison with other weight-management medicines.^↗ Read the reviewed studies and limitations →	Three selected publications report four randomized phase 3 trials in adults with chronic idiopathic constipation or irritable bowel syndrome with constipation.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports examine pramlintide alongside insulin in diabetes. Two are year-long adjunctive-treatment trials; the third evaluates an experimental automated insulin-and-pramlintide system and is not interchangeable with routine labeled treatment.^↗^↗^↗ Read the reviewed studies and limitations →	Three selected reports cover early retatrutide studies and the later TRANSCEND-T2D-1 phase 3 diabetes trial. Populations, comparators and primary endpoints differ across the studies.^↗^↗^↗ Read the reviewed studies and limitations →	A bounded review of two sponsor-funded randomized trials: STEP 1 for weight change and SELECT for cardiovascular outcomes.^↗^↗ Read the reviewed studies and limitations →	Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.^↗^↗ Read the reviewed studies and limitations →	A bounded review of sponsor-funded Phase 3 studies in rare genetic obesity syndromes: two small single-arm trials with withdrawal periods and one randomized trial followed by an open-label period.^↗^↗ Read the reviewed studies and limitations →	Four selected phase 2 and phase 3 reports examine survodutide in obesity and liver disease. Weight, MRI liver-fat and histological endpoints are different outcomes and should not be treated as interchangeable.^↗^↗^↗^↗ Read the reviewed studies and limitations →	No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage →	A bounded review of two randomized fracture trials in postmenopausal women with osteoporosis, including one placebo comparison and one active comparison with risedronate.^↗^↗ Read the reviewed studies and limitations →	A bounded review of two randomized placebo-controlled trials in adults living with HIV and abdominal fat accumulation.^↗^↗ Read the reviewed studies and limitations →	A bounded review of two sponsor-funded randomized Phase 3 trials: one in adults with obesity without diabetes and one in adults with type 2 diabetes treated with diet and exercise alone.^↗^↗ Read the reviewed studies and limitations →	No Human Evidence Review published here. This does not mean no human research exists. Inspect the profile’s review coverage →	Three selected placebo-controlled trials examined intrathecal ziconotide for severe refractory pain. Intrathecal delivery and the studied populations are essential context; these are not general-use pain studies.^↗^↗^↗ Read the reviewed studies and limitations →
Trial phases at observation	Phase 2: 1 selected record Phase 3: 1 selected record 7 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 2 selected records Phase 2: 1 selected record 14 of 16 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 1 selected record 1 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 1 selected record Phase 3: 1 selected record Phase 4: 1 selected record 3 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 2 selected records Phase 3: 2 selected records 4 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 1 selected record Phase 2: 1 selected record Phase 3: 1 selected record Phase 4: 1 selected record 6 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 2 selected records Phase 3: 1 selected record Phase 4: 1 selected record 5 of 9 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 4: 2 selected records Not applicable: 1 selected record 47 of 50 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 3 selected records Not applicable: 1 selected record 27 of 31 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 2 of 2 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 2 selected records 11 of 13 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 29 selected records Phase 1: 8 selected records Phase 3: 7 selected records Not applicable: 5 selected records Phase 4: 3 selected records 67 of 114 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 2 selected records Phase 3: 2 selected records Not applicable: 1 selected record 10 of 15 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 4: 7 selected records Phase 3: 3 selected records Not applicable: 2 selected records Phase 1: 2 selected records Phase 2: 1 selected record 64 of 79 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Not applicable: 1 selected record Phase 4: 1 selected record 4 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 5 selected records Phase 1: 1 selected record 6 of 12 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 3 selected records Phase 3: 3 selected records Not applicable: 1 selected record 4 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 2 selected records Phase 3: 1 selected record Phase 4: 1 selected record 53 of 57 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 2 selected records Phase 1: 1 selected record Phase 3: 1 selected record 2 of 6 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 3 selected records Phase 1: 2 selected records 2 of 7 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 3 selected records Phase 3: 1 selected record 8 of 12 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Not applicable: 1 selected record Phase 3: 1 selected record 3 of 5 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 4 selected records 1 of 5 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 8 selected records Phase 3: 8 selected records Phase 2: 6 selected records Phase 4: 3 selected records Not applicable: 2 selected records 72 of 98 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 0 of 0 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 3 selected records Phase 2: 1 selected record Phase 4: 1 selected record 9 of 14 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 4 selected records Phase 1: 1 selected record 3 of 8 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 1 selected record Phase 2: 1 selected record 0 of 1 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 3: 4 selected records Phase 4: 3 selected records Phase 2: 2 selected records 64 of 73 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 1: 1 selected record Phase 3: 1 selected record 9 of 11 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 11 selected records Phase 4: 5 selected records Phase 1: 2 selected records Phase 3: 2 selected records Early Phase 1: 1 selected record 48 of 67 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	Phase 2: 4 selected records 6 of 10 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →	No phase values available in this selected collection. 4 of 4 selected trial records lack structured phase detail. A record can list more than one phase. Inspect the cited trial observations →
Regulatory records	U.S. label record^↗ 1 connected Drugs@FDA applications 1 Federal Register documents 16 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 2 Federal Register documents 11 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Not an FDA-approved drug^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 2 Federal Register documents 1 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Unapproved new drug in cited enforcement record^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 1 Federal Register documents 39 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. accelerated approval for a specified Barth syndrome population^↗ 0 connected Drugs@FDA applications 2 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 5 connected Drugs@FDA applications 10 Federal Register documents 5 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding-list review for non-injectable routes^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 10 connected Drugs@FDA applications 16 Federal Register documents 2 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 0 Federal Register documents 3 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Unapproved new drug in cited enforcement record^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 3 connected Drugs@FDA applications 2 Federal Register documents 3 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 24 connected Drugs@FDA applications 18 Federal Register documents 6 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 3 connected Drugs@FDA applications 4 Federal Register documents 28 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 13 connected Drugs@FDA applications 13 Federal Register documents 2 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 3 Federal Register documents 20 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	China: approval reported by local government sources^↗↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 27 connected Drugs@FDA applications 10 Federal Register documents 2 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 3 Federal Register documents 14 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 2 Federal Register documents 11 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 5 connected Drugs@FDA applications 13 Federal Register documents 19 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 4 Federal Register documents 10 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	Investigational^↗ 0 connected Drugs@FDA applications 0 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	FDA compounding assessment in the cited records^↗ 0 connected Drugs@FDA applications 1 Federal Register documents 0 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 6 connected Drugs@FDA applications 6 Federal Register documents 8 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 3 Federal Register documents 9 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 2 connected Drugs@FDA applications 8 Federal Register documents 22 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 5 Federal Register documents 7 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →	U.S. label record^↗ 1 connected Drugs@FDA applications 1 Federal Register documents 6 DailyMed label versions Record counts do not establish approval for an ingredient, use, or formulation. Inspect regulatory connections →
Coverage gaps	No selected records in: Safety. Missing coverage is not evidence of absence. How do fracture outcomes and harms compare with other treatments over longer follow-up and in populations outside these selected trials?^↗^↗^↗ Does the bone-density improvement observed in ATOM translate into fewer fractures in men?^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. How durable are benefits and harms in broader EPP populations, including those underrepresented in the trials?^↗^↗^↗^↗ What do controlled studies establish in indications beyond EPP, and how do combination treatments affect attribution?^↗^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. How durable are effects after treatment ends, and what do longer studies show about serious harms?^↗^↗^↗^↗ How do results differ by formulation, population, attrition and the analysis of missing outcomes?^↗^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Do adequately powered controlled human trials reproduce any claimed benefit and characterize harms over meaningful follow-up?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. How do the magnitude of symptom changes, treatment discontinuation and patient preferences affect interpretation?^↗^↗^↗ Which longer-term harms and populations remain inadequately characterized?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Do larger and longer trials confirm durability, characterize uncommon harms, and show outcomes after treatment stops?^↗ How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?^↗^↗^↗^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Which findings apply to the exact molecular form and formulation being discussed?^↗^↗ Do controlled studies demonstrate patient-important benefits and adequately assess longer-term harms?^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. What do longer-term studies establish for populations and outcomes outside these three selected reports?^↗^↗^↗ How do later trial analyses relate to their original cohorts, and which findings have independent replication?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Which confirmatory results establish clinical benefit in the Barth syndrome population?^↗^↗^↗ How do study population, attrition and the absence of a control group affect the extension findings?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Are the preparations and study populations sufficiently comparable to combine these reports?^↗^↗ Do larger, longer randomized trials reproduce clinically meaningful sleep improvements?^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Which translated or related reports describe the same participants?^↗^↗ Do controlled studies assess patient-important outcomes and adequately report adverse events?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Which populations, if any, have durable patient-important benefits beyond glycemic control, and how do outcomes change after treatment discontinuation?^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Regulatory, Safety. Missing coverage is not evidence of absence. Which outcomes are supported by adequately controlled studies of a clearly identified GHK-Cu formulation?^↗^↗^↗ How do route, co-ingredients, study size, and follow-up limit what can be concluded about benefits and harms?^↗^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do current product labels distinguish rescue and diagnostic uses and age-specific indications?^↗^↗^↗ What do larger real-world studies establish about failures, harms and untrained-caregiver use?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Literature metadata, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Are there adequately controlled studies for proposed uses outside postoperative bowel recovery?^↗^↗ How do route, formulation and follow-up affect what can be concluded about harms?^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do formulation, indication and prior-treatment differences affect applicability?^↗^↗^↗ What do complete trial reports and current labels add about harms and longer follow-up?^↗^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do the compared approaches affect long-term patient-important outcomes, harms, and treatment persistence beyond the reviewed follow-up windows?^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. What additional trials address irritable bowel syndrome and other age groups?^↗^↗ How do current regulatory labels and longer follow-up refine the safety assessment?^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do benefits and harms vary in lower-risk populations, after discontinuation, and over follow-up beyond the reviewed trials?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. How do the monotherapy and fixed-combination regulatory records differ?^↗^↗ What do the broader diabetes program and subsequent Parkinson trials establish?^↗^↗ Inspect coverage and missing fields →	No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. What do full trial reports establish about attrition, estimands and discontinuation?^↗^↗ What do subsequent trials and jurisdiction-specific agency records establish?^↗^↗ Inspect coverage and missing fields →	No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. How do dated regulatory decisions differ by jurisdiction and indication?^↗^↗^↗^↗ What do full reports establish about missing outcomes, uncommon harms and durability?^↗^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. What evidence directly evaluates administered MOTS-c in humans, separately from exercise and endogenous biomarker studies?^↗^↗^↗ How do assay methods, confounding and population differences affect observed associations?^↗^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do long-term symptoms, clinical outcomes, treatment burden, and harms compare in broader acromegaly populations not selected through a responder run-in?^↗^↗ Inspect coverage and missing fields →	No selected records in: Literature metadata, Regulatory, Safety. Missing coverage is not evidence of absence. How do the original trial and selected extension differ in participant retention and outcome analysis?^↗^↗ What do full reports establish about missing outcomes, sustained histologic changes and longer-term clinical events?^↗^↗ Inspect coverage and missing fields →	No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. What do larger, longer controlled trials establish about sustained weight changes and uncommon adverse events?^↗ Do head-to-head trials support any comparative benefit or tolerability claim?^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. What do current labels establish about pediatric restrictions and serious diarrhea?^↗^↗^↗ How durable are outcomes beyond the randomized treatment periods?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. What do the current label and complete trial reports establish about severe hypoglycemia and discontinuation?^↗^↗^↗ Can longer studies reproduce the automated-delivery findings and assess patient-important outcomes?^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Do Phase 3 trials confirm durability, rare harms, and clinically important outcomes across more diverse populations?^↗^↗ How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?^↗^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. How do benefits and harms change after discontinuation, across populations excluded from these trials, and over longer follow-up?^↗^↗ Inspect coverage and missing fields →	No selected records in: Clinical trials, Safety. Missing coverage is not evidence of absence. Can adequately randomized, masked studies reproduce the reported functional effects?^↗^↗ What do complete reports establish about missing outcomes, concomitant care and safety?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. How durable are benefits and harms across each genetic subgroup, and which baseline features predict response in these exceptionally small populations?^↗^↗ Inspect coverage and missing fields →	No selected records in: Regulatory, Safety. Missing coverage is not evidence of absence. Do Phase 3 trials confirm durable clinical outcomes, clarify fibrosis effects, and characterize harms across broader populations?^↗^↗ How do participant flow, missing outcomes, protocol history and linked corrections affect interpretation of the selected reports?^↗^↗^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. How do fracture outcomes, harms, and persistence compare across broader osteoporosis populations and after the reviewed treatment windows?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Do the imaging changes translate into durable clinical benefits, and what are the longer-term effects in the studied population?^↗^↗ Inspect coverage and missing fields →	All four record lanes appear; coverage is still selective. Missing coverage is not evidence of absence. What are the durability, post-discontinuation outcomes, and uncommon harms across broader populations and longer follow-up?^↗^↗ Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. Inspect coverage and missing fields →	No selected records in: Safety. Missing coverage is not evidence of absence. What do current regulatory warnings specify about psychiatric and neurological risks?^↗^↗^↗ How do longer observational reports address durability, discontinuation and uncommon harms?^↗^↗^↗ Inspect coverage and missing fields →
Review and check dates	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 14, 2026. Review source snapshots checked: September 14, 2026. Integrity checked: September 14, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 18, 2026. Review source snapshots checked: August 18, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: Not available. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 18, 2026. Review source snapshots checked: August 18, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 29, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: September 15, 2026. Status evidence → Human evidence reviewed through: August 19, 2026. Review source snapshots checked: August 19, 2026. Integrity checked: August 19, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence review dates: not available. These dates do not imply continuous monitoring.	Status sources checked through: July 22, 2026. Status evidence → Human evidence reviewed through: September 15, 2026. Review source snapshots checked: September 15, 2026. Integrity checked: September 15, 2026. Review dates and source snapshots → These dates do not imply continuous monitoring.

Share this page’s URL to preserve your selection. Each evidence cell links to the cited source or its detailed evidence view.

Canonical profiles

41 deterministic maps

Open the research atlas →

2017–2026 selected source window

Abaloparatide

60 dated records3/4 lanes present10 source years

Trials 9 2 with phase · 2 with status
Trial-publication graph 3 exact source-declared NCT ↔ PMID links
PubMed 33 9 with bibliography
Drugs@FDA 1 exact reviewed application connections
FDA history 11 dated AP submissions · 23 official documents
DailyMed 16 exact SPL version receipts

Missing selected lanes: Safety.